March 2, 2020 / 2:43 PM / a month ago

BRIEF-Meiragtx Announces Priority Medicines, Advanced Therapy Medicinal Product Designations Granted By European Medicines Agency To Aav-Rpgr Gene Therapy

March 2 (Reuters) - MeiraGTx Holdings PLC:

* MEIRAGTX ANNOUNCES PRIORITY MEDICINES (PRIME) AND ADVANCED THERAPY MEDICINAL PRODUCT (ATMP) DESIGNATIONS GRANTED BY THE EUROPEAN MEDICINES AGENCY TO AAV-RPGR GENE THERAPY FOR THE TREATMENT OF X-LINKED RETINITIS PIGMENTOSA

* MEIRAGTX HOLDINGS PLC - PRIME DESIGNATION GRANTED BASED ON CLINICAL DATA FROM ONGOING PHASE 1/2 TRIAL OF AAV-RPGR Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below